Biocon has sold 80,00,000 equity shares of Syngene International (Syngene) in open market through block deal mechanism on December 10, 2024. Post this transaction, the shareholding of the Company in Syngene shall stand at 52.46%.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.